Exclusion Criteria:~* Any disability that prevented the participant from completing all study requirements.~*
Current medical or neurological condition that could have impacted cognition or performance on cognitive
assessments.~* Advanced, severe progressive or unstable disease that may have interfered with the safety,
tolerability and study assessments, or put the participant at special risk.~* History of malignancy of any
organ system, treated or untreated, within 60 months prior to screening.~* History of hypersensitivity to any
of the investigational drugs or their excipients / adjuvant or to drugs of similar chemical classes.~*
Indication or on current treatment with ChEIs and/or another AD treatment (e.g. memantine).~* Contraindication
or intolerance to MRI or PET investigations (with fluorinated radio ligands).~* Brain MRI results showing
findings unrelated to AD that, in the opinion of the Investigator could have been a leading cause to future
cognitive decline, pose a risk to the participant, or prevent a satisfactory MRI assessment for safety
monitoring.~* Suicidal Ideation in the past six months or Suicidal Behavior in the past two years, prior to
screening.~* A positive drug screen at Screening, if, in the Investigator's opinion, this was due to drug
abuse.~* Significantly abnormal laboratory results at Screening, or infection not as a result of a temporary
condition.~* Current clinically significant ECG findings. For Cohort - I only: Participants with previous organ
transplantation or stem cell transplantation, or indication for treatment with anti-coagulants.~For Cohort - II
only: Participants with depigmenting or hypopigmenting conditions (e.g. albinism vitiligo) or active / history
of chronic urticarial in the past year.
